Emphasizing HER2 Testing as A Premier Diagnostic Approach To mCRC - AJMC.com Managed Markets Network

Testing prioritization and frequency are highlighted in Dr Ciombor’s final insights for this HER2 biomarker focus.

Kristen Ciombor, MD:HER2 amplification in metastatic colorectal cancer is typically found in about 2% to 3% of all comers. However, if you see RAS wild-type disease, its enriched in that population. … [+3567 chars]

full article...